Seelos Therapeutics shares are trading higher after the company announced it signed a material transfer agreement to supply SLS-002 for the Department of Defense's military and veterans adaptive platform clinical trial for PTSD.
Portfolio Pulse from Benzinga Newsdesk
Seelos Therapeutics' stock is rising following the announcement of a material transfer agreement to supply SLS-002 for a Department of Defense clinical trial focused on PTSD.
September 24, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seelos Therapeutics' shares are up after signing a material transfer agreement to supply SLS-002 for a Department of Defense clinical trial targeting PTSD.
The agreement with the Department of Defense is a significant development for Seelos Therapeutics, as it involves supplying their product SLS-002 for a clinical trial. This could lead to increased visibility and potential future contracts, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100